Works about THERAPEUTIC use of antineoplastic agents


Results: 5000
    1
    2

    Globe artichoke.

    Published in:
    Journal of Primary Health Care, 2025, v. 17, n. 2, p. 202, doi. 10.1071/HC25100
    By:
    • Lee, E Lyn;
    • Barnes, Jo
    Publication type:
    Article
    3

    Cosibelimab.

    Published in:
    American Journal of Health-System Pharmacy, 2025, v. 82, n. 13, p. 638, doi. 10.1093/ajhp/zxaf055
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16

    Latest findings in chemotherapy.

    Published in:
    Journal of Obstetrics & Gynaecology Research, 2024, v. 50, p. 79, doi. 10.1111/jog.16028
    By:
    • Morisada, Tohru
    Publication type:
    Article
    17
    18
    19
    20
    21
    22
    23
    24
    25

    Metastasis of endometrial cancer to breast: A rare case.

    Published in:
    Journal of Obstetrics & Gynaecology Research, 2023, v. 49, n. 5, p. 1452, doi. 10.1111/jog.15621
    By:
    • Erdoğan, Özgür;
    • Balci, Mücahit Furkan;
    • Özgüzer, Alp;
    • Özdaş, Emel;
    • Görgülü, Gökşen;
    • Sanci, Muzaffer
    Publication type:
    Article
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43

    Prognostic Nutrition Index as a Biomarker for Treatment Sensitivity to Chemotherapy and Nivolumab as the First-Line Treatment in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter Study.

    Published in:
    Oncology, 2025, v. 103, n. 6, p. 469, doi. 10.1159/000541544
    By:
    • Nakazawa, Nobuhiro;
    • Sano, Akihiko;
    • Kumakura, Yuji;
    • Yamashita, Toshiki;
    • Tanaka, Naritaka;
    • Saito, Kana;
    • Kimura, Akiharu;
    • Kasuga, Kengo;
    • Nakazato, Kenji;
    • Yoshinari, Daisuke;
    • Shimizu, Hisashi;
    • Ubukata, Yasunari;
    • Hosaka, Hisashi;
    • Shiraishi, Takuya;
    • Sakai, Makoto;
    • Sohda, Makoto;
    • Shirabe, Ken;
    • Saeki, Hiroshi
    Publication type:
    Article
    44
    45

    Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.

    Published in:
    Oncology, 2025, v. 103, n. 6, p. 456, doi. 10.1159/000541018
    By:
    • Persano, Mara;
    • Casadei-Gardini, Andrea;
    • Tada, Toshifumi;
    • Suda, Goki;
    • Shimose, Shigeo;
    • Kudo, Masatoshi;
    • Rossari, Federico;
    • Yoo, Changhoon;
    • Cheon, Jaekyung;
    • Finkelmeier, Fabian;
    • Lim, Ho Yeong;
    • Presa, José;
    • Masi, Gianluca;
    • Bergamo, Francesca;
    • Amadeo, Elisabeth;
    • Vitiello, Francesco;
    • Kumada, Takashi;
    • Sakamoto, Naoya;
    • Iwamoto, Hideki;
    • Aoki, Tomoko
    Publication type:
    Article
    46
    47

    Poor Tolerability of Lenvatinib in Elderly Patients with Advanced Hepatocellular Carcinoma after Disease Progression following First-Line Atezolizumab Plus Bevacizumab: A Multicenter Study.

    Published in:
    Oncology, 2025, v. 103, n. 4, p. 311, doi. 10.1159/000541455
    By:
    • Kato, Daisuke;
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Okayama, Kohei;
    • Okumura, Fumihiro;
    • Nagura, Yoshihito;
    • Sobue, Satoshi;
    • Hayashi, Katsumi;
    • Kusakabe, Atsunori;
    • Hasegawa, Izumi;
    • Matoya, Sho;
    • Mizoshita, Tsutomu;
    • Kimura, Yoshihide;
    • Kondo, Hiromu;
    • Ozasa, Atsushi;
    • Kawamura, Hayato;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Kataoka, Hiromi
    Publication type:
    Article
    48
    49
    50